Orchestra BioMed Holdings (OBIO) Net Income towards Common Stockholders (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Net Income towards Common Stockholders of -$20.7 million for Q1 2026, down 10.14% year-over-year from -$23.0 million in Q1 2025, and down 423.1% quarter-over-quarter from $6.4 million in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$20.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 10.14% year-over-year to -$20.7 million; the TTM figure through Mar 2026 stood at -$56.4 million (up 27.42% YoY), while the FY2025 annual figure was -$53.0 million, up 13.22% from the prior year.
- Net Income towards Common Stockholders declined to -$20.7 million in Q1 2026 per OBIO's latest filing, from $6.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $6.4 million in Q4 2025 and bottomed at -$25.2 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged -$14.5 million across 5 years, with a median of -$16.1 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 8300.5% — and 2025, when it soared 139.71%.
- Orchestra BioMed Holdings' Net Income towards Common Stockholders stood at -$10.1 million in 2022, then fell by 23.72% to -$12.5 million in 2023, then decreased by 28.98% to -$16.1 million in 2024, then surged by 139.71% to $6.4 million in 2025, then plunged by 423.1% to -$20.7 million in 2026.
- Business Quant data shows OBIO's Net Income towards Common Stockholders at -$20.7 million in Q1 2026, $6.4 million in Q4 2025, and -$20.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -24.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.08 Mn |
| Mar 31, 2026 | -20.66 Mn |
| Dec 31, 2025 | 5.99 Mn |
| Sep 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -19.36 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -16.16 Mn |
| Sep 30, 2024 | -15.43 Mn |
| Jun 30, 2024 | -15.96 Mn |
| Mar 31, 2024 | -13.41 Mn |
| Dec 31, 2023 | -11.37 Mn |
| Sep 30, 2023 | -13.61 Mn |
| Jun 30, 2023 | -12.96 Mn |
| Mar 31, 2023 | -11.55 Mn |
| Dec 31, 2022 | -9.83 Mn |
| Sep 30, 2022 | -10.07 Mn |
| Jun 30, 2022 | -7.63 Mn |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -92,045.00 |
| Sep 30, 2021 | -94,445.00 |